Quanta Dialysis Raises $60 Million for Kidney Care
Quanta Dialysis Technologies, a pioneering company based in Warwick, UK, is dedicated to revolutionizing the realm of kidney care through its innovative Quanta™ Dialysis System. Recently, the company achieved a significant milestone by successfully raising over $60 million in its Series E funding round. This financial boost has been led by prominent investors including Novo Holdings, Glenview Capital, and b2venture, alongside valuable contributions from existing investors who believe in the vision and potential of Quanta. The newly acquired funds will primarily be allocated to expanding the company’s commercial footprint in the United States, while also fostering further innovations in the dialysis technology sector.
Under the leadership of CEO Alejandro Galindo, Quanta Dialysis Technologies is unwavering in its mission to enhance kidney care accessibility for patients in various settings.
The Quanta Dialysis System is designed to offer unparalleled clinical versatility, delivering kidney replacement therapy that meets the needs of diverse healthcare environments. Notably, the device is engineered to be operated by a wide range of users, which significantly broadens the scope of how dialysis can be provided. This user-friendly approach not only facilitates the delivery of essential care but also empowers patients by bringing dialysis treatment directly to them, whether in hospitals, clinics, or the comfort of their own homes.
Highlighting its commitment to innovation, Quanta Dialysis Technologies made headlines in 2022 when it received clearance for the first and only FDA-cleared device capable of performing intermittent hemodialysis (IHD), sustained low efficiency dialysis (SLED), and continuous renal replacement therapy (CRRT) without the need for bags. This groundbreaking advancement in dialysis technology was followed by another significant achievement in 2024, when Quanta obtained FDA clearance for its home hemodialysis (HHD) system, which features a high dialysate flow rate of 500 mL/min. These advancements represent not only a leap forward in the quality of care provided to kidney patients but also exemplify Quanta's ongoing commitment to enhancing patient outcomes and experiences through innovative solutions.
They've invested in Quanta Dialysis Technologies
Get to know these Healthtech investors
Click here for a full list of 6,908+ startup investors in the UK